encorafenib
Sign in to saveAlso known as LGX-818, LGX818
Encorafenib, sold under the brand name Braftovi, is an anti-cancer medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 539.151779
- Has use
- medication
Show 6 more facts
- isomeric SMILES
- C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=CC(=CC(=C3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC
- canonical SMILES
- CC(C)N1C=C(C(=N1)C2=CC(=CC(=C2F)NS(=O)(=O)C)Cl)C3=NC(=NC=C3)NCC(C)NC(=O)OC
- chemical formula
- C₂₂H₂₇ClFN₇O₄S
- Commons category
- Encorafenib
- subject has role
- protein kinase inhibitors
- medical condition treated
- Colorectal cancer
via Wikidata · CC0
~7 min read
Encyclopedic overview
5 sectionsContents
- Medical uses
- Pharmacology
- History
- Clinical trials
- References
{{Drugbox | image = Encorafenib.svg | image_class = skin-invert-image | width = 240 | alt = | caption =
| pronounce = | tradename = Braftovi | Drugs.com = | MedlinePlus = a618040 | DailyMedID = Encorafenib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = Antineoplastic agent | ATC_prefix = L01 | ATC_suffix = EC03 | ATC_supplemental =
Excerpted from Wikipedia’s “encorafenib” article, available under the CC BY-SA 4.0 licence.